

WEST Search History

DATE: Tuesday, August 06, 2002

Set Name Query

side by side

Hit Count Set Name

result set

DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L7 (Juniper\$(malt) and elastase not l6

2 L7

L6 (Juniper\$(malt) same elastase

1 L6

DB=USPT; PLUR=YES; OP=ADJ

L5 (Juniper\$(malt) same elastase

4 L5

L4 6375948.pn.

1 L4

L3 (almond|rose|clove|hawthorn|betula|gambir) same elastase

4 L3

L2 L1 same inhib\$

7 L2

L1 (almond|rose|clove|hawthorn|betula|gambir) same hair

305 L1

END OF SEARCH HISTORY

*****STN Columbus*****

FILE 'HOME' ENTERED AT 08:45:07 ON 06 AUG
2002

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT
AUTHORIZED

COST IN U.S. DOLLARS SINCE
FILE TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21 0.21

INDEX 'ADISALERTS, ADISINSIGHT,
ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
 BIOBUSINESS, BIOCOMMERCE, BIOSIS,
BIOTECHABS, BIOTECHDS, BIOTECHNO,
CABA,
 CANCERLIT, CAPLUS, CEABA-VTB, CEN,
CIN, CONFSCI, CROPB, CROPU, DDFB,
 DDFU, DGENE, DRUGB, DRUGLAUNCH,
DRUGMONOG2, ...'
ENTERED AT 08:45:32 ON 06 AUG 2002

63 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings
or to view

search error messages that display as 0* with SET
DETAIL OFF.

=> s (almond or rose or clove or hawthorn or betula
or gambir or juniper? or malt) (10a) (elastase (5a)
inhib?)

2 FILE BIOSIS
12 FILES SEARCHED...
4 FILE CAPLUS
24 FILES SEARCHED...
2 FILE EMBASE
39 FILES SEARCHED...
1 FILE IFIPAT
2 FILE MEDLINE
50 FILES SEARCHED...

1 FILE SCISEARCH
1 FILE TOXCENTER
3 FILE USPATFULL
61 FILES SEARCHED...
3 FILE WPIDS
3 FILE WPINDEX

10 FILES HAVE ONE OR MORE ANSWERS.
63 FILES SEARCHED IN STNINDEX

L1 QUE (ALMOND OR ROSE OR CLOVE OR
HAWTHORN OR BETULA OR GAMBIR OR
JUNIPER? O
 R MALT) (10A) (ELASTASE (5A) INHIB?)

=> d rank

F1 4 CAPLUS
F2 3 USPATFULL
F3 3 WPIDS
F4 3 WPINDEX
F5 2 BIOSIS
F6 2 EMBASE
F7 2 MEDLINE
F8 1 IFIPAT
F9 1 SCISEARCH
F10 1 TOXCENTER

=> file f1 f3-10

COST IN U.S. DOLLARS SINCE
FILE TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.95 8.16

FILE 'CAPLUS' ENTERED AT 08:54:29 ON 06
AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR
STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR
DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL
SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 08:54:29 ON 06 AUG
2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BIOSIS' ENTERED AT 08:54:29 ON 06 AUG
2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS
INC.(R)

FILE 'EMBASE' ENTERED AT 08:54:29 ON 06
AUG 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All
rights reserved.

FILE 'MEDLINE' ENTERED AT 08:54:29 ON 06
AUG 2002

FILE 'IFIPAT' ENTERED AT 08:54:29 ON 06 AUG
2002

COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent
Services (IFI)

FILE 'SCISEARCH' ENTERED AT 08:54:29 ON 06
AUG 2002

COPYRIGHT (C) 2002 Institute for Scientific
Information (ISI) (R)

FILE 'TOXCENTER' ENTERED AT 08:54:29 ON
06 AUG 2002

COPYRIGHT (C) 2002 ACS

=> s l1

5 FILES SEARCHED...

L2 16 L1

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 11 DUP REM L2 (5 DUPLICATES
REMOVED)

ANSWERS '1-4' FROM FILE CAPLUS
ANSWERS '5-7' FROM FILE WPIDS
ANSWERS '8-9' FROM FILE BIOSIS
ANSWER '10' FROM FILE IFIPAT
ANSWER '11' FROM FILE SCISEARCH

=> d bib abs 1-11

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT
2002 ACS

AN 2000:271984 CAPLUS

DN 132:269859

TI Elastase inhibitors for cosmetics

IN Moriwaki, Shigeru; Tsuji, Shoko; Shibuya,
Yusuke; Kusuoku, Hiroshi;

Kanazawa, Satoshi

PA Kao Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE

APPLICATION NO. DATE

PI JP 2000119189 A2 20000425 JP 1998-
283981 19981006

JP 2969451 B2 19991102

AB This invention relates to an ***elastase***

inhibitor which

includes steam distillates or pressed products of
ginger rhizome,

almond hydrolyzates, Sanguisorba
rhizome, Syzygium aromaticum,

Rosa multiflora fruit, Crataegus oxyantha, and
Betula alba. The above

plant exts. at the concn. .ltoreq. 5 % evapn.
residue equiv., show

.gtoreq. 25 % of elastase inhibitory activities

using N-succinyl-Ala-Ala-

Ala-p-nitroanilide substrate.

L3 ANSWER 2 OF 11 CAPLUS COPYRIGHT
2002 ACS

AN 2000:252036 CAPLUS

DN 132:269854

TI Antiaging cosmetics containing plant extracts
and soy proteins

IN Sugiyama, Hiromichi; Ohara, Yasuhiro; Sakai,
Yuji

PA Pola Chemical Industries, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE

APPLICATION NO. DATE

PI JP 2000109420 A2 20000418 JP 1998-
297645 19981005

AB This invention relates to antiaging cosmetics
comprising (1) elastase

inhibitors selected from the group consisting of
soybean protein and

Engelhardtia chrysolepis exts. and (2) peroxide
formation inhibitors

selected from the group consisting of exts. of
ginseng, Scutellaria root,
and white birch.

L3 ANSWER 3 OF 11 CAPLUS COPYRIGHT
2002 ACS

AN 1999:579115 CAPLUS

DN 131:219009

TI Antiaging agents containing clove extracts and
cosmetics containing the
extracts

IN Inomata, Shinji; Ota, Masahiro

PA Shiseido Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE

APPLICATION NO. DATE

PI JP 11246385 A2 19990914 JP 1998-
67793 19980303

AB Antiaging agents contain solvent exts. of
Syzygium aromaticum (clove) as

active ingredients. Cosmetics contg. the exts.
are also claimed.

Clove exts. ***inhibit***
elastase and maintain

elasticity of skin. Antiwrinkle and elasticity-
increasing effects of a
cream foundation contg. an EtOH ext. of clove
were tested in female
volunteers.

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT
2002 ACS

AN 1961:44010 CAPLUS

DN 55:44010

OREF 55:8569h-i

TI The nature of the elastase inhibitor

AU Viola, S.; Salvini, L.

CS Univ. Florence

SO Giorn. gerontol. (1960), 8, 659-64

DT Journal

LA Unavailable

AB In the serums of 50 human subjects detns.
were made of serum antielastase

activity by the method of Hall (CA 49, 7611e)

and of serum heparinoids by

the method of S. and V. (CA 51, 1441i). A

direct relation was found

between these levels, the elastase inhibitor

activity increasing at higher

concns. of heparinoids. In parallel with clearing-
factor activity, the

elastase ***inhibitor*** in serum

rose when the

subjects were injected with 100 mg. heparin and
fell slightly after oral

administration of 100 g. butter. The serum

elastase inhibitor may be a

mucopolysaccharide of heparinlike nature.

L3 ANSWER 5 OF 11 WPIDS (C) 2002

THOMSON DERWENT

AN 2001-253773 [26] WPIDS

DNC C2001-076365

TI Cosmetics for improving skin aging, comprises
component elastase inhibitor

and hydroxy carboxylic acid, ketone carboxylic
acid, amido derivative,

amine derivative or guanidine derivative.

DC D21

PA (KAOS) KAO CORP

CYC 1

PI JP 2001058920 A 20010306 (200126)* 11p

ADT JP 2001058920 A JP 1999-233745
19990820

PRAI JP 1999-233745 19990820

AN 2001-253773 [26] WPIDS

AB JP2001058920 A UPAB: 20010515

NOVELTY - The cosmetics comprises
component (A) containing

elastase ***inhibitor*** such as
almond, Sanguisorba
officinalis, ***clove***, Rosae multiflorae
fructus or Crataegus

oxyacantha and component (B) containing

hydroxy carboxylic acid, ketone

carboxylic acid, amido derivative, amine
derivative or guanidine

derivative.

USE - As cosmetics for improving skin aging.

ADVANTAGE - The cosmetics effectively
prevents aging of skin.

Dwg.0/0

L3 ANSWER 6 OF 11 WPIDS (C) 2002

THOMSON DERWENT

AN 1999-424883 [36] WPIDS

DNC C1999-125262

TI Elastase inhibitor - can prevent ageing of skin
and can be used as

ointment for skin.

DC B04 D21

PA (MARU-N) MARUZEN SEIYAKU KK

CYC 1

PI JP 11171758 A 19990629 (199936)* 5p

ADT JP 11171758 A JP 1997-362341 19971212

PRAI JP 1997-362341 19971212

AN 1999-424883 [36] WPIDS

AB JP 11171758 A UPAB: 19990908

Elastase ***inhibitor*** comprises
extract of ***Betula***

platyphylla Sukatchev var japonica,

Cinnamomum cassia Blume, Tilia cordata

Mill, Tilia platyphyllos Scop, Tilia europaea L.

Tilia japonica Simonkai,

Eriobotrya japonica Lindley or Hamamelis
virginiana L. Extraction is

conducted by using water, methanol or ethanol.

Extract is incorporated in

ointment composition in an amount of 0.01 to 10
wt %.

ADVANTAGE - The inhibitor can prevent
aging of skin and can be used

as ointment for skin.

Dwg.0/0

L3 ANSWER 7 OF 11 WPIDS (C) 2002

THOMSON DERWENT

AN 1999-593870 [51] WPIDS

DNC C1999-173618

TI Elastase inhibitor for skin ageing prevention -
has active ingredients or

extracts of ginger, hydrolyzing almond, white
birch and clove.

DC B04 D21

PA (KAOS) KAO CORP; (KAOS) KAO KK

CYC 1

PI JP 2969451 B1 19991102 (199951)* 4p

JP 2000119189 A 20000425 (200031) 4p

ADT JP 2969451 B1 JP 1998-283981 19981006;

JP 2000119189 A JP 1998-283981

19981006

PRAI JP 1998-283981 19981006

AN 1999-593870 [51] WPIDS

AB JP 2969451 B UPAB: 19991207

NOVELTY - The inhibitor includes active
ingredients or extracts of ginger,

hydrolyzing almond, Sanguisorba officinalis,

clove, rosae

multiflorae fructus, ***hawthorn*** and a

white birch. The

inhibitor exhibits 25% or more of

elastase suppression

activity at a concentration of 5% or less.

USE - For suppressing skin ageing due to
ultraviolet rays.

ADVANTAGE - Has outstanding elastase
inhibitory effect and also

excels in safety.

Dwg.0/0

L3 ANSWER 8 OF 11 BIOSIS COPYRIGHT

2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE

AN 1990:418335 BIOSIS
 DN BA90:79136
 TI LONG-TERM REPLACEMENT THERAPY IN
 HOMOZYGOUS ALPHA-1 ANTITRYPSIN
 DEFICIENCY
 INFLUENCE ON PROTEINASE
 ANTIPROTEINASE EQUILIBRIUM IN PLASMA
 AND SPUTUM.
 AU BRAUN J; WELLE S; VAN WEES J;
 WINTERHOFF R; WOOD W G; DALHOFF K;
 WIESSMANN
 K-J
 CS KLINIK FUER INNERE MEDIZIN, ZENTRUM
 INNERE MEDIZIN DER MEDIZINISCHEN
 UNIVERSITAET, RATZEBURGER ALLEE 160.
 SO DMW (DTSCH MED WOCHENSCHR).
 (1990) 115 (23), 889-894.
 CODEN: DDMWDF. ISSN: 0012-0472.
 FS BA; OLD
 LA German
 AB Long-term replacement with human .alpha.1-
 antitrypsin (60 mg/kg once a
 week intravenously) was carried out in seven
 patients with homozygous
 .alpha.1-antitrypsin deficiency (7 males, mean
 age 50.8 [40-59] years) and
 progressive pulmonary emphysema for an
 average of 16 (13-20) weeks. After
 at least 12 weeks' therapy the concentrations of
 .alpha.1-antitrypsin,
 elastase-.alpha.1-antitrypsin complex, .alpha.2-
 macroglobulin, lactoferrin
 and elastase inhibition capacity in plasma and
 sputum were assayed, these
 assays being performed before starting the
 .alpha.1-antitrypsin infusion
 and at various times during the following week.
 After the infusion the
 plasma concentration of .alpha.1-antitrypsin
 rose from a depressed initial
 level (mean 1.22 g/l) to a level approximately
 five times higher (median
 after 1 hour: 5.96 g/l, $P < 0.001$), and then
 declined exponentially,

though it never fell below the threshold of 35%
 of normal which is
 regarded as the protective level. Elastase
 inhibition capacity displayed
 similar changes ($r = 0.85$). The sputum
 concentration of
 .alpha.1-antitrypsin rose more slowly than the
 plasma concentration: from
 the initial lower level (median 8 mg/l) it reached
 a maximum about four
 times higher after 24 hours (median 36 mg/l; P
 < 0.02). ***Elastase***
 inhibition capacity ***rose*** from 151
 mIU/ml (median) before
 the .alpha.1-antitrypsin infusion to 450 mIU/ml
 at 24 hours. These
 findings suggest that .alpha.1-antitrypsin
 replacement will have
 beneficial effects on proteinase-antiproteinase
 equilibrium. Determination
 of elastase inhibition capacity in the sputum is
 suitable for monitoring
 dosage during replacement therapy.

L3 ANSWER 9 OF 11 BIOSIS COPYRIGHT
 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 2

AN 1988:349119 BIOSIS
 DN BA86:44597
 TI PLASMA LEVELS OF MAIN GRANULOCYTE
 COMPONENTS DURING CARDIOPULMONARY
 BYPASS.
 AU RIEGEL W; SPILLNER G; SCHLOSSER V;
 HOERL W H
 CS MEDIZINISCHE UNIVERSITAETSKLIN.,
 HUGSTETTERSTR. 55, D-7800 FREIBURG I.BR.,
 WEST GERMANY.
 SO J THORAC CARDIOVASC SURG. (1988) 95
 (6), 1014-1019.
 CODEN: JTCSAQ. ISSN: 0022-5223.
 FS BA; OLD
 LA English
 AB Plasma levels of granulocyte lactoferrin,
 myeloperoxidase, and elastase in
 .alpha.1-proteinase inhibitor complex were
 compared with C3a and C5a

levels in 10 patients undergoing cardiopulmonary bypass. At the end of the operation, plasma levels of lactoferrin increased from 97.0 \pm 22.8 to 1257 \pm 139.8 ng/ml, myeloperoxidase increased from 37.1 \pm 4.3 to 170.9 \pm 34.9 ng/ml, and ***elastase*** in .alpha.-proteinase ***inhibitor*** complex ***rose*** from 89.4 \pm 7.4 to 43.78 \pm 97.3 ng/ml. There was also a significant anaphylatoxin formation. To investigate the relationship between complement and granulocyte activation, patients undergoing cardiopulmonary bypass received the calcium channel blocker nifedipine (orally and intravenously) and the antiplatelet drug dipyridamole. The continuous infusion of nifedipine (5.91 \pm 0.53 μ g/kg body weight per hour) caused significantly lower levels of elastase in .alpha.-proteinase inhibitor complex and lactoferrin but not anaphylatoxin. Dipyridamole was without effect on complement and granulocyte activation during cardiopulmonary bypass. Our data demonstrate inhibition of granulocyte activation during cardiopulmonary bypass by continuous infusion of nifedipine, even in the presence of complement activation.

L3 ANSWER 10 OF 11 IFIPAT COPYRIGHT 2002 IFI
 AN 10012522 IFIPAT;IFIUDB;IFICDB
 TI ANTI-AGING AGENT; PLANT EXTRACT
 INF Inomata; Shinji, Yokohama-shi, JP
 IN Inomata Shinji (JP)
 PAF Unassigned
 PA Unassigned Or Assigned To Individual (68000)
 AG Harold C. Wegner FOLEY & LARDNER, Washington Harbour, Suite 500, 3000 K Street, N.W. Washington, DC, 20007-5109, US

PI US 2001012524 A1 20010809
 AI US 2001-814220 20010322
 RLI US 1998-125786 19980827
 CONTINUATION
 WO 1997-JP4859 19971225 Section 371
 PCT Filing UNKNOWN
 PRAI JP 1996-358052 19961227
 FI US 2001012524 20010809
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 FS APPLICATION
 CLMN 3
 2 Figure(s).
 FIG. 1 is a graph showing the ***elastase*** ***inhibiting*** activity of an Uncaria ***gambir*** Roxburgh extract in comparison with fetal calf serum.
 FIG. 2 shows the ***elastase*** ***inhibiting*** activity at low concentration of Uncaria ***gambir*** Roxburgh extract.
 AB This invention relates to an anti-aging agent, more particularly, it relates to an anti-aging agent having an elastase inhibiting action and capable of maintaining the tautness and elasticity of the skin and maintaining a youthful state of the skin. According to the present invention, there is provided an antiaging agent containing, as an effective ingredient, a solvent extract of Uncaria gambir Roxburgh.
 CLMN 3 2 Figure(s).
 FIG. 1 is a graph showing the ***elastase*** ***inhibiting*** activity of an Uncaria ***gambir*** Roxburgh extract in comparison with fetal calf serum.
 FIG. 2 shows the ***elastase*** ***inhibiting*** activity at low concentration of Uncaria ***gambir*** Roxburgh extract.

L3 ANSWER 11 OF 11 SCISEARCH
 COPYRIGHT 2002 ISI (R)
 AN 91:237535 SCISEARCH
 GA The Genuine Article (R) Number: FE985
 TI REPLACEMENT THERAPY WITH ALPHA-1-
 PROTEINASE-INHIBITOR IN PATIENTS WITH
 HOMOZYGOUS ALPHA-1-ANTITRYPSIN
 DEFICIENCY
 AU BRAUN J (Reprint); WELLE S; WOOD W G;
 DALHOFF K; WIESSMANN K J
 CS MED UNIV LUBECK, INNERE MED KLIN,
 RATZEBURGER ALLEE 160, W-2400 LUBECK,
 GERMANY (Reprint)
 CYA GERMANY
 SO ATEMWEGS-UND LUNGENKRANKHEITEN,
 (1990) Vol. 16, No. 7, pp. 303-305.
 DT Article: Journal
 LA German
 REC Reference Count: 9
 *ABSTRACT IS AVAILABLE IN THE ALL AND
 IALL FORMATS*
 AB Long-term replacement therapy with human
 alpha-1-proteinase inhibitor
 (60 mg/kg i.v. once weekly) was carried out in 9
 patients with homozygous
 alpha-1-antitrypsin deficiency and progressive
 pulmonary emphysema. The
 concentration of alpha-1-proteinase inhibitor
 and the elastase-inhibition
 capacity (EIC) were assayed in plasma and
 sputum before
 alpha-1-PI-infusion and at various times during
 the following week. After
 the infusion the plasma concentration of alpha-
 1PI rose from a depressed
 initial level (median 1.22 g/l) to a level
 approximately five times higher
 (median after 1 hour: 5.96 g/l; $p < 0.001$), and
 then declined
 exponentially. Elastase-inhibition capacity
 displayed similar changes (r
 = 0.85). In sputum the concentration of alpha-
 1PI rose more slowly than
 the plasma concentration; from the initial level
 (median 8 mg/l) it

reached a maximum about four times higher
 after 24 hours (median 36 mg/l;
 $p < 0.02$). ***Elastase*** - ***inhibition***
 capacity ***rose***
 from 151 mIU/ml (median) before alpha-1PI-
 infusion to 450 mIU/ml at 24
 hours. These findings suggest that replacement
 with alpha-1PI has a
 beneficial effect on proteinase-antiproteinase-
 equilibrium. The
 determination of the elastase-inhibition capacity
 in sputum is suitable
 for monitoring dosage during replacement
 therapy.

=> file stnguide
 COST IN U.S. DOLLARS SINCE
 FILE TOTAL

ENTRY
 SESSION
 FULL ESTIMATED COST
 56.69 64.85

DISCOUNT AMOUNTS (FOR QUALIFYING
 ACCOUNTS) SINCE FILE TOTAL
 ENTRY

SESSION
 CA SUBSCRIBER PRICE -
 2.48 -2.48

FILE 'STNGUIDE' ENTERED AT 08:55:30 ON 06
 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR
 CUSTOMER AGREEMENT
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL
 SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND
 FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Aug 2, 2002 (20020802/UP).

=> log y
 COST IN U.S. DOLLARS SINCE
 FILE TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.26 66.11

DISCOUNT AMOUNTS (FOR QUALIFYING
ACCOUNTS) SINCE FILE TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00 -2.48

STN INTERNATIONAL LOGOFF AT 09:08:08 ON
06 AUG 2002